Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
iptacopan - CFB inhibitor
NCT04578834 APPLAUSE-IgAN (CLNP023A2301)
Indication
Phase
IgA nephropathy
Phase 3
iptacopan - CFB inhibitor
NCT04817618 APPEAR-C3G (CLNP023B12301)
Indication
C3 glomerulopathy
Phase 3
References
Abbreviations
Other
Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine
collection)
Experimental: iptacopan 200mg b.i.d.
Placebo Comparator: Placebo to iptacopan 200mg b.i.d.
Patients with native C3G
Phase
Patients
450
Patients
68
Primary
Outcome
Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine
collection) at 9 months
Measures
Read-out
Milestone(s)
Publication
Arms
Intervention
Target
Patients
Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated
over 24 months
Arm 1 - LNP023 200mg BID
Arm 2 - Placebo BID
Primary IgA Nephropathy patients
2023 (primary endpoint for US initial submission, 9 months UPCR)
2025 (24 months)
Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1:
Study Design
Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1:
IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT
ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND
EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Read-out
Milestone(s)
2023
Publication
TBD
46 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation